ES2196053T3 - Procedimiento para el tratamiento de trastornos del cuerpo humano o animal mediante la administracion de aminoacidos. - Google Patents

Procedimiento para el tratamiento de trastornos del cuerpo humano o animal mediante la administracion de aminoacidos.

Info

Publication number
ES2196053T3
ES2196053T3 ES95904697T ES95904697T ES2196053T3 ES 2196053 T3 ES2196053 T3 ES 2196053T3 ES 95904697 T ES95904697 T ES 95904697T ES 95904697 T ES95904697 T ES 95904697T ES 2196053 T3 ES2196053 T3 ES 2196053T3
Authority
ES
Spain
Prior art keywords
glutamine
liver
treatment
administration
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95904697T
Other languages
English (en)
Inventor
Leeuwen Paulus Aloisius Ma Van
Alexander Petrus Jacob Houdijk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
STICHTING ZOFIA
Original Assignee
STICHTING ZOFIA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8216591&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2196053(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by STICHTING ZOFIA filed Critical STICHTING ZOFIA
Application granted granted Critical
Publication of ES2196053T3 publication Critical patent/ES2196053T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCION SE REFIERE AL USO DE GLUTAMINA O DE UN EQUIVALENTE DE GLUTAMINA PARA EL TRATAMIENTO DE ESTADOS ENFERMOS DONDE HAY UN FLUJO SANGUINEO REDUCIDO AL HIGADO O DONDE HAY BAJOS NIVELES DE PLASMA DE ARGININA. DICHOS ESTADOS ENFERMOS COMPRENDEN ENDOTOXEMIA, INFLAMACION SISTEMICA, ALTO NIVEL DE ARGINASA EN PLASMA, BACTEREMIA, ICTERICIA, TRASPLANTE DE HIGADO, RESECCION DEL HIGADO, ENFERMEDAD INTESTINAL INFLAMATORIA, TRASPLANTES EN GENERAL, AUMENTO DE PRODUCCION DE CITOQUINA O ESTEATOSIS DEL HIGADO. TAMBIEN SE PROPORCIONA UNA COMPOSICION ALIMENTICIA ADECUADA PARA MEJORAR LA FUNCION DEL HIGADO, QUE CONTIENE, COMO UNIDAD DE DOSIFICACION DIARIA, DE 15-300 G DE GLUTAMINA O DE UN EQUIVALENTE DE GLUTAMINA, JUNTO A UNA CANTIDAD DE HIDRATOS DE CARBONO, PROTEINAS, LIPIDOS, VITAMINAS, MINERALES Y FIBRAS VEGETALES, LO CUAL ES SUFICIENTE PARA CUMPLIR UN REQUISITO ALIMENTICIO MINIMO DIARIO.
ES95904697T 1994-01-11 1995-01-11 Procedimiento para el tratamiento de trastornos del cuerpo humano o animal mediante la administracion de aminoacidos. Expired - Lifetime ES2196053T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94200042 1994-01-11

Publications (1)

Publication Number Publication Date
ES2196053T3 true ES2196053T3 (es) 2003-12-16

Family

ID=8216591

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95904697T Expired - Lifetime ES2196053T3 (es) 1994-01-11 1995-01-11 Procedimiento para el tratamiento de trastornos del cuerpo humano o animal mediante la administracion de aminoacidos.

Country Status (5)

Country Link
US (1) US6001878A (es)
EP (2) EP1362587A1 (es)
DE (1) DE69530570T2 (es)
ES (1) ES2196053T3 (es)
WO (1) WO1995018608A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2089297A (en) * 1997-03-17 1998-10-12 Yun K. Tam Composition for prevention of hepatic steatosis
US20020119933A1 (en) * 2000-07-28 2002-08-29 Butler Terri L. Compositions and methods for improving cardiovascular function
US7431939B1 (en) 2000-09-28 2008-10-07 Mississippi State University Inhibition of systemic infections in humans and vertebrates by dietary fibers
GB2371767A (en) * 2001-02-02 2002-08-07 Labman Automation Ltd Dissolving materials by application of agitation and ultrasound
EP1372641A4 (en) 2001-03-05 2004-08-25 Stephen P Ernest ENTERAL FORMULATION
US20050059610A1 (en) * 2003-09-12 2005-03-17 Paul Wischmeyer Glutamine for use in treating injury
US20050124694A1 (en) * 2003-12-09 2005-06-09 Arthur Vanmoor Method of accelerating metabolism of alcohol
WO2006016904A2 (en) * 2004-04-14 2006-02-16 Uab Research Foundation Activators of hexosamine biosynthesis as inhibitors of injury induced by ischemia or hemorrhagic shock
US8445536B2 (en) * 2005-03-31 2013-05-21 Ajinomoto Co., Inc. Arginine-containing compositions and methods for increasing blood flow using same
JP5046174B2 (ja) * 2005-03-31 2012-10-10 味の素株式会社 アルギニン含有血流増加用組成物
EP2077110A4 (en) * 2006-09-29 2012-06-27 Ajinomoto Kk GLUTAMINE-CONTAINING COMPOSITION FOR INCREASING BLOOD FLOW
US9616041B2 (en) * 2011-12-19 2017-04-11 Emmaus Medical, Inc. Methods and compositions for the treatment of diverticulosis
US20140357571A1 (en) * 2012-01-09 2014-12-04 N.V. Nutricia Glutamine enriched nutritional composition for preterm infants
EP2612560A1 (en) * 2012-01-09 2013-07-10 N.V. Nutricia Glutamine enriched nutritional composition for preterm infants
EP4241838A3 (en) 2016-02-01 2023-12-20 Bioenergy Life Science, Inc. Use of ribose for treatment of subjects having congestive heart failure
CN115266706A (zh) * 2022-05-31 2022-11-01 安徽天润化学工业股份有限公司 一种快速检测阴离子型聚丙烯酰胺水解度的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687782A (en) * 1984-12-10 1987-08-18 Nutri-Fuels Systems, Inc. Nutritional composition for enhancing skeletal muscle adaptation to exercise training
JPS61186320A (ja) * 1985-02-12 1986-08-20 Morishita Seiyaku Kk アミノ酸製剤
CA1285491C (en) * 1985-09-12 1991-07-02 Robert J. Smith Method of treating catabolic dysfunction
JPH01216924A (ja) * 1988-02-24 1989-08-30 Ajinomoto Co Inc 肝障害治療剤
IL94549A (en) * 1989-06-02 1996-08-04 Brigham & Womens Hospital A pharmaceutical preparation containing glutamine
US5157022A (en) * 1989-11-22 1992-10-20 Adrian Barbul Method for reducing blood cholesterol using arginine
EP0441119A3 (en) * 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
US5248697A (en) * 1990-09-20 1993-09-28 Brigham And Women's Hospital Enhancement of glutathione levels with glutamine
SE468881B (sv) * 1991-01-09 1993-04-05 Kabi Pharmacia Ab Anvaendning av vissa foereningar foer framstaellning av laekemedel foer behandling av endotoxininducerade effekter samt saett att avlaegsna endotoxiner ur diverse loesningar
DE9110794U1 (de) * 1991-08-31 1991-10-31 Grabarkiewicz, Gerda, 8520 Erlangen Mittel zur Prophylaxe gegen Alkohol-Schäden
JP3168669B2 (ja) * 1992-02-26 2001-05-21 味の素株式会社 肝再生促進剤
US5438042B1 (en) * 1993-10-08 1997-08-26 Sandoz Nutrition Ltd Enteral nutritional composition having amino acid profile

Also Published As

Publication number Publication date
EP1362587A1 (en) 2003-11-19
DE69530570D1 (de) 2003-06-05
WO1995018608A1 (en) 1995-07-13
US6001878A (en) 1999-12-14
EP0738146B1 (en) 2003-05-02
DE69530570T2 (de) 2004-03-18
EP0738146A1 (en) 1996-10-23

Similar Documents

Publication Publication Date Title
ES2196053T3 (es) Procedimiento para el tratamiento de trastornos del cuerpo humano o animal mediante la administracion de aminoacidos.
Murillo Ortiz et al. Recovery of bone and muscle mass in patients with chronic kidney disease and iron overload on hemodialysis and taking combined supplementation with curcumin and resveratrol
PT1131065E (pt) Fumaratos dialquilicos para o tratamento de doencas autoimunes
ATE267798T1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
BR9715022A (pt) Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada
Aral et al. Therapeutic effects of systemic vitamin k2 and vitamin d3 on gingival inflammation and alveolar bone in rats with experimentally induced periodontitis
BR0106681A (pt) Fórmula pediátrica e métodos para prover nutrição a pacientes pediátricos e para melhorar tolerância em pacientes pediátricos
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
ES2659353T3 (es) Métodos y formulaciones nutricionales para aumentar la eficacia y reducir los efectos secundarios del tratamiento del cáncer
DE69931907D1 (de) Zusammensetzungen aus hagebutten als anti-entzündliches natürliches arzneimittel zur erleichterung/verringerung von symptomen, die mit entzündungen und arthritis zusammenhängen
FI972744A0 (fi) Aminohappokokoonpanoja ja niiden käyttö kliinisessä ravinnossa
BRPI0416275A (pt) métodos de tratar, controlar ou prevenir um cáncer especìfico e uma doença associada com angiogênese indesejada
BR0316057A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e uma doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com a terapia de radiação, terapia hormonal, terapia biológica ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
Martini et al. Primary osteoblasts response to shock wave therapy using different parameters
Jeschke et al. Nutritional intervention high in vitamins, protein, amino acids, and ω3 fatty acids improves protein metabolism during the hypermetabolic state after thermal injury
BRPI0410761A (pt) uso de leucina, e, composição para administração entérica a pacientes
ES2220256T1 (es) Albumina humana terapeutica con baja actividad para la fijacion de aluminio.
DE3750426D1 (de) Mittel zur Verbesserung spezifischer Eigenschaften des Blutes.
US20110045099A1 (en) Nutraceutical composition and methods of use
Torrero et al. New developments in the treatment of osteoarthritis–focus on biologic agents
AR029160A1 (es) El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo
Baggott et al. Folic acid supplements are good (not bad) for rheumatoid arthritis patients treated with low-dose methotrexate
BR9917605A (pt) Composição substituta de plasma
RU97118495A (ru) Простагландинсодержащий препарат ветеринарного назначения "клатирам"
Ertugruloglu et al. Enhancement of Corchorus olitorius L. on osteogenic differentiation of MC3T3-E1 pre-osteoblast cells by increasing alkaline phosphatase and hydroxyproline